US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could Be Next
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could Be Next
HHS Secretary Xavier Becerra emphasized that the Biden administration's prescription drug policies are making a tangible impact on seniors and people with disabilities by reducing out-of-pocket costs.Monday, the U.S. Department of Health and Human Services (HHS) announced that Medicare enrollees will benefit from reduced prices on 54 drugs through Medicare Part B, effective from October 1, 2024, to December 31, 2024.
美國衛生及公衆服務部（HHS）宣佈，從2024年10月1日至12月31日，醫療保健服務部門將始於《藥品部分b》上爲54種藥物的價格提供優惠，醫療保險參保者受益。
The program aims to counter drug price hikes that exceed inflation, providing financial relief for over 822,000 Medicare beneficiaries who rely on these medications to treat conditions like cancer, osteoporosis, and pneumonia.
該計劃旨在應對超過通貨膨脹的藥品漲價，爲超過822,000名依賴這些藥物治療癌症、骨質疏鬆症和肺炎等疾病的醫保受益人提供財務上的救助。
Also Read: Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
閱讀更多：醫生在Novo Nordisk的Wegovy上爲心臟病患者爭取醫保覆蓋安排困難
HHS Secretary Xavier Becerra emphasized that the Biden administration's prescription drug policies are making a tangible impact on seniors and people with disabilities by reducing out-of-pocket costs.
衛生及公衆服務部長哈維爾·貝塞拉強調，拜登政府的處方藥政策通過降低個人支出成本，對減少老年人和殘障人士產生切實影響。
According to Chiquita Brooks-LaSure, CMS Administrator, some Medicare beneficiaries could see daily savings ranging from $1 to as much as $3,854 on drugs included in the rebate program.
依據康哲藥業管理局長夏奇塔·布魯克斯-拉舒爾的說法，一些醫療保險受益人在包含在折扣計劃中的藥物上，每天可節省1美元至3,854美元。
For example, a cancer patient using Novartis' AGs (NYSE:NVS) Kymriah could save up to $3,000.
例如，使用諾華公司的AGs（NYSE:NVS）Kymriah的癌症患者可以節省高達3,000美元。
Brooks-LaSure also noted that the law disincentivizes drug companies from raising prices faster than inflation, which helps protect Medicare beneficiaries from sharp price increases.
布魯克斯-拉舒爾還指出，該法律打擊藥品公司高於通貨膨脹的價格上漲，幫助保護醫療保險受益人免受價格大幅上漲的衝擊。
The Inflation Reduction Act's initiatives extend beyond 2024. In August, the administration reached new agreements to reduce prices for ten additional high-cost drugs.
通貨膨脹減緩法案的倡議超越了2024年。今年8月，政府達成新協議，爲額外十種高成本藥物降價。
Once these prices take effect in 2026, Medicare is projected to save an estimated $6 billion, while beneficiaries could see a reduction of $1.5 billion in out-of-pocket expenses.
一旦這些價格在2026年生效，據預測，Medicare 可能會節省約600億美元，而受益人可能會在個人費用方面看到150億美元的減少。
Starting in 2025, Medicare Part D enrollees will further benefit from a $2,000 annual cap on prescription drug costs, down from the current cap of $3,500 for those with high expenses.
從2025年開始，Medicare 第D部分的參保人將進一步受益於每年2000美元的處方藥費用上限，而不是目前對於高費用者爲3500美元的上限。
According to some analysts, Novo Nordisk A/S' (NYSE:NVO) blockbuster diabetes drug Ozempic might be included, along with several other well-known medications, in the next round of negotiations, which is set for 2027.
根據一些分析師的說法，**康哲藥業（NYSE:NVO）**的暢銷糖尿病藥物奧塞普可能會被納入，並與其他幾種知名藥物一起在2027年的下一輪談判中。
- TPG, GIC Agree To Buy Techem For $7.5B: Look To Expand 'Across Europe And Beyond'
- TPG、GIC同意以75億美元收購Techem：計劃在歐洲及其他地區擴張
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。
